Table 1.

Studies on long-term mortality in NAFLD. Tabulated studies are those with an average follow-up of 5 years or longer.

Author [ref]	Diagnosis	n	Cirrhosis Prevalence* n	Liver-related deaths N	Overall deaths n	Average F/U (years)
Adams et al. [1]	NALFD	420	21 (5%)	7 (1.7%)	53 (12.6)	7.6
Ekstedt et al. [2]	NAFLD	129	10 (7.8%)	2 (1.6%)	26 (20.2%)	13.7
Rafiq et al. [3]**	NAFLD	131	NR	12 (9.2%)	78 (59.5%)	18.5
Soderberg [4]	NAFLD	118	9 (7.6%)	9 (7.6%)	47 (39.8%)	21
	Total	798	40 (6%)	30 (3.8%)	204 (25.6%)	15.2
Teli et al [5]	Simple Steatosis	40	0	0	14 (35)	9.6
Ekstedt et al. [2]	Simple Steatosis	58	0	0	7 (12.1)	13.7
Dam-Larsen et al. [6]&	Simple Steatosis	170	2 (1.2%)	1 (0.6)	48 (28.2%)	20.7
Rafiq et al. [3]**	Simple Steatosis	74	NR	2 (2.7%)	42 (56.8%)	18.5
	Total	342	2 (0.7%)	3 (0.9%)	111 (32.5%)	15.6
Evans et al. [7]	NASH	26	1 (4%)	0 (0)	4 (15)	8.7
Ekstedt et al [2]	NASH	71	10 (14.1%)	2 (2.8%)	19 (26.8%)	13.7
Rafiq et al. [3]**	NASH	57	NR	10 (17.5%)	36 (63.2%)	18.5
Soderberg [4]	NASH	51	5 (9.8%)	3 (5.9%)	24 (47.1%)	21
	Total	205	16 (10.8%)	15 (7.3%)	83 (40.5 %)	15.5
Hui et al. [8]	Cirrhotic-stage NAFLD	23	100%	5 (21%)	6 (26%)	5.0
Sanyal et al. [9]	Cirrhotic-stage NAFLD	152	100%	22 (14.5%)	29 (19.1%)	10
Yatsuji et al. [10]#	Cirrhotic-stage NAFLD	68	100%	15 (22.1%)	19 (27.9%)	5.0
Soderberg [4]	Cirrhotic-stage NAFLD	9	100%	4 (44.4%)	8 (88.9%)	21
	Total	252	252 (100%)	46 (18.3%)	62 (24.6%)	10.25

^*cirrhosis prevalence includes all patients diagnosed with cirrhosis at both baseline and during follow-up. NAFLD denotes the inclusion of both patients with simple steatosis and patients with NASH.

^**Updated data from Mateoni et al. Gastroenterology 1999;116:1413-1419.

^&Updated data from Dam-Larsen et al. Gut 2004;53:750-755.

^#Updated analysis from Hashimoto et al. Hepatol Res 2005;33:72-76